160.65MMarket Cap-3.17P/E (TTM)
3.100High2.920Low281.39KVolume3.100Open2.970Pre Close841.68KTurnover0.87%Turnover RatioLossP/E (Static)53.37MShares9.69052wk High0.70P/B97.17MFloat Cap2.60052wk Low--Dividend TTM32.28MShs Float14.710Historical High--Div YieldTTM6.06%Amplitude1.450Historical Low2.991Avg Price1Lot Size
TScan Therapeutics Stock Forum
Benzinga· 1 min ago
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is high...
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...
Benzinga· 2 mins ago
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
NEWS
TScan Therapeutics Announces Closing of Upsized Public Offering
No comment yet